WHIPPANY, N.J.--(BUSINESS WIRE)--July 6, 2005--Medcon Telemedicine Technology, Inc., a global leader in cardiac image and information management solutions, announced today that it received U.S. Food and Drug Administration (FDA) clearance for its new hemodynamic monitoring system, Windsurfer. Windsurfer is marketed and sold separately, or together with Medcon’s TCS Symphony image management solution for unrivaled integration of cardiac images and data in the cath lab. “The market has witnessed a transformation in hemodynamic systems - they have gone from basic monitoring systems to integral parts of the complete catheterization process,” says Uzi Blumensohn, CEO Medcon Telemedicine Technology, Inc. “Significant portions of procedural data, as well as workflow procedures, are controlled by the hemodynamic monitoring system. That’s why it was a natural decision for Medcon to expand our current product offering to include Windsurfer, a new and powerful hemodynamic monitoring system. Windsurfer streamlines the cath lab workflow and aggregates all data into one cardiac electronic medical record, complimenting our existing image and information management solution.”
